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Abstract: Objective: Cholestasis is associated with increased liver
injury and morbidity after partial hepatectomy (PH), yet bile acids
(BAs) are emerging as important mediators of liver regeneration.
Fibroblast growth factor 15 (Fgf15, human FGF19) is a BA-induced
ileum-derived enterokine that governs BA metabolism. We evaluated
the relevance of Fgf15 in the preservation of BA homeostasis after PH
and its potential role in the regenerative process. Design: Liver regen-
eration after PH was studied in Fgf15/ and Fgf15+/+ mice. The
effects of the BA sequestrant cholestyramine and adenovirally deliv-
ered Fgf15 were examined in this model. The role of Fgf15 in BA-
induced liver growth was tested in Fgf15/ mice upon cholic acid
(CA) feeding. The direct mitogenic effect of Fgf15 was evaluated in
cultured mouse hepatocytes and cholangiocytes. Results: Fgf15/
mice showed marked liver injury and mortality after PH accompa-
nied by persistently elevated intrahepatic BA levels. Cholestyramine
feeding and adenovirally delivered Fgf15 reduced BA levels and sig-
niﬁcantly prevented this lethal outcome. Fgf15 also reduced mortal-
ity after extensive hepatectomy in Fgf15+/+ animals. Liver growth
elicited by CA feeding was signiﬁcantly diminished in Fgf15/ mice.
Proliferation of hepatocytes and cholangiocytes was also noticeably
reduced in CA-fed Fgf15/ mice. Fgf15 induced intracellular signal-
ing and proliferation of cultured hepatocytes and cholangiocytes.
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Preoperative administration of this enterokine to patients undergo-
ing liver resection might be useful to reduce damage and foster
regeneration.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V.
Post-resection liver failure (PLF) is a feared and potentially lethal
complication occurring in up to 9% of patients undergoing partial
hepatic resection [1]. Insufﬁcient quantity or quality of the rem-
nant liver resulting in inadequate liver regeneration (LR) plays a
major role in its pathogenesis. An elaborate study by Uriarte and
colleagues in Gut demonstrates that tight control of hepatic bile
salt homeostasis is crucial to prevent bile salt toxicity and allow
successful LR, and provides a rationale for prevention of PLF.
Already recognized by the ancient Greeks (‘‘The myth of Pro-
metheus’’), the liver has unparalleled capacity for regrowth fol-
lowing injury or loss of tissue mass [2]. The regenerative
potential of the liver is exploited in surgical treatment of hepatic
and biliary tract tumors, as well as in living-donor and split liver
transplantation. The rodent partial hepatectomy (PH) model is
frequently used to study LR, and consists of resection of the
median and left lateral lobes. The resultant loss of two-thirds of
hepatic mass triggers a proliferative response in the remnant
liver that restores liver mass in approximately one week. While
LR after PH involves activation and expansion of existing paren-
chymal cells, activation of hepatic progenitor cells is required
for compensatory regrowth after extensive hepatocytic damage,
e.g., acute toxic insult or chronic liver injury [3].
A multitude of interconnected signaling pathways responding
to cytokines, growth and metabolic factors, is involved in the ini-
tiation, progression, and termination of the regenerative response
after PH [2]. LR is impaired in partially hepatectomized animals
with external biliary diversion and/or bile duct ligation, and in
patients undergoing resection for obstructive hepatobiliary
malignancies [4]. This underscores the importance of an intact
enterohepatic circulation for LR and alludes to involvement of
intestine- and/or liver-derived signaling molecules. Earlier stud-
ies in mice established that bile salt feeding induces a hyperplas-
tic response in the liver in the absence of a regenerative stimulus,
and accelerates liver regrowth after PH [5]. This relies on the
presence of the bile salt-activated transcription factor Fxr
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Fig. 1. Enterohepatic circulation of bile salts results in the activation of a
feedback loop comprising ileum-derived FGF19/FGF15 (here denoted as FGF)
and hepatic FXR that represses de novobile salt synthesis. After partial
hepatectomy, transient hepatic accumulation of bile salts results in activation
of FXR that is required for efﬁcient liver regeneration. Loss of feedback control in
Fgf15/ mice results in unrepressed bile salt synthesis and toxicity due to
detrimental build-up of bile salts. Apart from disturbed bile salt homeostasis,
direct proliferative effects of FGF19/FGF15 appear to underlie defective liver
regeneration following partial hepatectomy in Fgf15/ mice.
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(Farnesoid X Receptor), with a recent study revealing that intestinal
and liver Fxr are both required for efﬁcient LR after PH [6]. Given
the involvement of FXR in a multitude of processes, the mecha-
nisms underlying delayed LR in Fxr/ mice are expected to be
complex but include perturbed bile salt homeostasis and failure
to induce Foxm1b, a key regulator of cell cycle progression [5,7].
Inherent to the amphipathic nature of bile salts, tight regula-
tion of their intracellular levels is warranted to prevent hepato-
toxicity that may impede LR. The FXR-induced enterokine
FGF19 (Fibroblast Growth Factor 19, termed Fgf15 in rodents)
plays an important role in the negative feedback loop that con-
trols hepatic bile salt synthesis. Consequentially, disturbances
in the enterohepatic circulation perturb this control mechanism.
Unlike in humans where FGF19 is also expressed in the cholestat-
ic liver, in adult mice Fgf15 is solely expressed in the small
intestine [8]. Using mice with global deﬁciency of Fgf15 and
(re)gain-of-function studies, Uriarte et al. now demonstrate that
Fgf15 is responsible for – at least part of – the effects of bile salts
on liver (re)growth and acts as a direct mitogen for hepatocytes
and cholangiocytes in vitro [9].
Two-thirds PH resulted in marked liver injury and mortality
(ca. 70%) in Fgf15/ mice in the ﬁrst 48 hr post-resection, with
mortality notably higher than previously reported for Fxr/ mice
(30% mortality within 7 days) [5,9]. Liver regrowth in surviving
Fgf15/ mice was slower in the early phase of LR, with normal
liver mass restoration after 5–7 days. While a transient accumu-
lation of bile salts in the liver accompanied PH in control mice,
hepatic bile salt levels were higher prior to PH and immediately
rose and remained elevated throughout the early phase of LR in
Fgf15/ animals. This strongly suggests that Fgf15-mediated
reduction of bile salt synthesis is needed to prevent bile salt tox-
icity in the remnant liver. The toxic build-up of bile salts likely
accounted for the lethal outcome of PH in Fgf15/ mice. In agree-
ment with this, lowering of hepatic bile salt levels by feeding of a
sequestrant prior to PH resulted in drastic improvement in 3-day
survival (30?80%). Suggestive of a role beyond bile salt homeo-
stasis, FGF19 had a direct mitogenic action on primary hepato-
cytes and cultured cholangiocytes. The aggregated data
demonstrate that intestine-derived Fgf15 is crucial for efﬁcient
LR after PH, and emphasize the importance of tight control of bile
salt homeostasis in recovery from liver injury (Fig. 1).
It remains to be determined if these effects of Fgf15 are
exerted through its alleged receptor Fgfr4, which appears dis-
pensable for liver regrowth after PH [10]. Immunoglobulin-like
domain IIIc-spliced FGFRs can act as alternative receptors for
FGF19 but these are predominantly expressed by stromal cells
rather than epithelial cells. Other intriguing questions to be
explored include the role of FGF15 in progenitor cell-mediated
LR, and the interplay between miRNAs and FGF19 signaling in
the context of LR. Of particular interest is miR-34a, which is
induced in the termination phase of LR and interferes with
FGF19 signaling by targeting the expression of an essential co-
receptor [11,12]. In addition, upregulation of this miRNA in stea-
totic liver and impairment of FGF19 signaling may contribute to
defective regeneration in the fatty liver [12].
The ﬁndings of Uriarte et al. provide a rationale for prevention
and treatment of PLF by targeting the FXR/FGF19 gut-liver axis.
Factors conferring risk for PLF and impairing LR include small
remnant liver volume, advanced age, steatosis, cholestasis, and
cirrhosis [1]. FXR agonism largely overcomes the age-related LR
defects after PH in mice [7]. Moreover, FXR activation or FGF191122 Journal of Hepatology 2013administration has beneﬁcial effects on hepatic lipid and bile salt
homeostasis [13,14]. Therapeutic strategies resulting in persis-
tent elevation of circulating FGF19 levels, however, require com-
prehensive study of undesirable proliferative actions of FGF19.
Pre-neoplastic changes in the liver (after 4 months) and develop-
ment of hepatocellular carcinoma at 10–12 months of age, are
apparent in mice with chronic overexpression of FGF19 [15].
The role of FGF19 in human hepatocarcinogenesis is currently
unclear. The short-term application of FXR agonists or FGF19 in
reducing PLF-related mortality should be considered. As a proof
of principle, Uriarte et al. demonstrate that (adenoviral) Fgf15
delivery improves 3-day survival (0?46%) in the 85% hepatec-
tomy model of acute liver failure [9].Conﬂict of interest
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